Dermata Therapeutics Inc. Warrant (DRMAW)
Company Info
Highlights
-$2.16
-$11.65M
$0.01 - $0.03
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Dermata Therapeutics Inc. Warrant (DRMAW) returned -2.03% year-to-date (YTD) and 45.00% over the past 12 months.
DRMAW
-2.03%
-2.68%
64.77%
45.00%
-40.86%
N/A
N/A
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of DRMAW, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 100.68% | -17.51% | -28.57% | -14.86% | -2.68% | -2.03% | |||||||
| 2024 | 257.14% | -36.80% | -39.87% | -0.00% | -14.74% | 72.84% | -4.29% | -35.82% | 16.28% | 24.00% | -29.03% | 68.18% | 111.43% |
| 2023 | 173.97% | 2.25% | 22.00% | -64.73% | 87.50% | -24.24% | -20.00% | -10.00% | -2.78% | -31.43% | 75.00% | -66.67% | -52.05% |
| 2022 | -6.42% | -53.39% | -14.51% | -8.30% | -39.39% | 23.79% | -23.84% | 16.67% | -3.06% | -66.11% | 52.80% | -70.33% | -96.60% |
| 2021 | -2.70% | -23.15% | 2.41% | -23.54% | -33.85% | -61.27% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of DRMAW is 60, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Dermata Therapeutics Inc. Warrant (DRMAW) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Dermata Therapeutics Inc. Warrant. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Dermata Therapeutics Inc. Warrant was 99.64%, occurring on Dec 6, 2022. The portfolio has not yet recovered.
The current Dermata Therapeutics Inc. Warrant drawdown is 98.96%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.64% | Nov 4, 2021 | 191 | Dec 6, 2022 | — | — | — |
| -42.69% | Aug 31, 2021 | 40 | Oct 27, 2021 | 5 | Nov 3, 2021 | 45 |
| -27.02% | Aug 16, 2021 | 3 | Aug 18, 2021 | 5 | Aug 25, 2021 | 8 |
| -1.79% | Aug 26, 2021 | 1 | Aug 26, 2021 | 1 | Aug 27, 2021 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Dermata Therapeutics Inc. Warrant over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Dermata Therapeutics Inc. Warrant is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for DRMAW relative to other companies in the Biotechnology industry. Currently, DRMAW has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DRMAW in comparison with other companies in the Biotechnology industry. Currently, DRMAW has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |